Literature DB >> 6148215

Human hepatic cytochrome P-450 composition as probed by in vitro microsomal metabolism of warfarin.

L S Kaminsky, D A Dunbar, P P Wang, P Beaune, D Larrey, F P Guengerich, R G Schnellmann, I G Sipes.   

Abstract

Human liver microsomal fractions from 27 renal donors (tissue obtained post mortem) and from six cancer patients (tissue obtained during surgery) were used to investigate human hepatic cytochrome P-450 isozyme compositions. In vitro microsomal metabolism of the R and S enantiomers of warfarin to dehydrowarfarin and 4'-, 6-, 7-, 8-, and 10-hydroxywarfarin is catalyzed by cytochrome P-450 isozymes and was used as the basis for evaluating similarities and differences between human cytochrome P-450 isozyme compositions. The mean hepatic cytochrome P-450 concentration from postmortem samples was not significantly different from that of surgical patients (0.51 +/- 0.16 vs. 0.35 +/- 0.14 nmol/mg protein), but the NADPH-cytochrome P-450 reductase activity of the former was significantly higher than that of the latter (141 +/- 56 vs. 29 +/- 6 nmol cytochrome c reduced/min/mg protein). In general, the microsomal preparations were overall stereoselective for R warfarin metabolism. The stereoselectivities for formation of the individual metabolites of the R enantiomer were 6-, 8-, and 10-hydroxywarfarin and the S enantiomer were 4'- and 7-hydroxywarfarin. Of the 33 microsomal preparations, 21 exhibited qualitatively similar warfarin metabolite profiles with 6R- and 7S-hydroxywarfarin having the highest formation rates. Some of the preparations exhibited markedly different metabolite profiles, the most notable having 10R-hydroxywarfarin as the major metabolite. Based on the known warfarin metabolite profiles of five purified cytochrome P-450 isozymes, the isozyme composition of the microsomes can be estimated. The majority of the microsomal preparations apparently had similar isozyme compositions but some preparations were markedly different.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6148215

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  13 in total

Review 1.  Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.

Authors:  Mike Ufer
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 2.  Assessment of liver metabolic function. Clinical implications.

Authors:  J Brockmöller; I Roots
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

3.  Identification of cytochrome P450 oxidoreductase gene variants that are significantly associated with the interindividual variations in warfarin maintenance dose.

Authors:  Xiuling Zhang; Lei Li; Xinxin Ding; Laurence S Kaminsky
Journal:  Drug Metab Dispos       Date:  2011-05-11       Impact factor: 3.922

4.  Proximal Tubular Vacuolization and Hypersensitivity to Drug-Induced Nephrotoxicity in Male Mice With Decreased Expression of the NADPH-Cytochrome P450 Reductase.

Authors:  Liang Ding; Lei Li; Senyan Liu; Xiaochen Bao; Kathleen G Dickman; Stewart S Sell; Changlin Mei; Qing-Yu Zhang; Jun Gu; Xinxin Ding
Journal:  Toxicol Sci       Date:  2020-02-01       Impact factor: 4.849

5.  Influence of genetic polymorphisms in cytochrome P450 oxidoreductase on the variability in stable warfarin maintenance dose in Han Chinese.

Authors:  Wu-Tao Zeng; Qing Xu; Cheng-Hsun Li; Wei-Yan Chen; Xiu-Ting Sun; Xiang Wang; Yi-Ying Yang; Hui Shi; Zhi-Sheng Yang
Journal:  Eur J Clin Pharmacol       Date:  2016-08-04       Impact factor: 2.953

Review 6.  The influence of nutrition on the systemic availability of drugs. Part II: Drug metabolism and renal excretion.

Authors:  I Walter-Sack
Journal:  Klin Wochenschr       Date:  1987-11-02

7.  Identification of an inducible form of cytochrome P-450 in human liver.

Authors:  P B Watkins; S A Wrighton; P Maurel; E G Schuetz; G Mendez-Picon; G A Parker; P S Guzelian
Journal:  Proc Natl Acad Sci U S A       Date:  1985-09       Impact factor: 11.205

Review 8.  Influence of diet and nutritional status on drug metabolism.

Authors:  I Walter-Sack; U Klotz
Journal:  Clin Pharmacokinet       Date:  1996-07       Impact factor: 6.447

9.  Further insight into the stereoselective interaction between warfarin and cimetidine in man.

Authors:  I Niopas; S Toon; M Rowland
Journal:  Br J Clin Pharmacol       Date:  1991-10       Impact factor: 4.335

10.  The effect of multiple doses of donepezil HCl on the pharmacokinetic and pharmacodynamic profile of warfarin.

Authors:  P J Tiseo; K Foley; L T Friedhoff
Journal:  Br J Clin Pharmacol       Date:  1998-11       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.